BNP Paribas Knock-Out 6MK/ DE000PE3VMN4 /
2024-03-28 7:48:00 PM | Chg.+0.02 | Bid7:56:26 PM | Ask7:56:26 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.53EUR | +0.57% | 3.55 Bid Size: 36,000 |
3.56 Ask Size: 36,000 |
MERCK CO. D... | 93.5613 - | 2078-12-31 | Call |
GlobeNewswire
8:00 AM
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-12-12
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
2023-12-04
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
2023-11-13
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA